Experimental Drug Shows Potential to Delay Alzheimer's Onset by 50%

A study on gantenerumab highlights early intervention benefits for genetically predisposed individuals, though further research is needed.

Gantenerumab, an anti-amyloid drug, reduced the risk of Alzheimer's symptoms by 50% in participants treated for eight years.
The study focused on individuals with a rare genetic mutation that guarantees early-onset Alzheimer's between their 30s and 50s.
Limitations included a small sample size, external controls, and lower initial doses, complicating definitive conclusions.
30% of participants experienced amyloid-related imaging abnormalities (ARIA), though no life-threatening events occurred.
While Roche discontinued gantenerumab in 2023, ongoing trials are testing other anti-amyloid drugs like lecanemab for preventive potential.